| 貨號(hào) | 規(guī)格 | 價(jià)格 | 上海 | 北京 | 武漢 | 南京 | 購(gòu)買(mǎi)數(shù)量 |
|---|---|---|---|---|---|---|---|
| S80158-2mg | 99% | ￥224.00 | 5 | - | - | - |
|
| S80158-5mg | 99% | ￥304.00 | 5 | - | - | - |
|
| S80158-10mg | 99% | ￥432.00 | 4 | - | - | - |
|
| S80158-25mg | 99% | ￥720.00 | 6 | - | - | - |
|
| S80158-50mg | 99% | ￥1200.00 | 貨期：2-3天 | - | - | - |
|
| S80158-100mg | 99% | ￥1920.00 | 貨期：2-3天 | - | - | - |
|
Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively
| 產(chǎn)品描述： | Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點(diǎn)： | p110δ:2.5 nM (IC50);p110γ:27.4 nM (IC50);p110β:85 nM (IC50);p110α:1602 nM (IC50);PI3K | ||||||||||||||||||||
| 參考文獻(xiàn)： | 1. Pillinger G, et al. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection. Oncotarget. 2016 Jun 28;7(26):39784-39795. 2. G?ckeritz E, et al. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells. Int J Cancer. 2015 Nov 1;137(9):2234-42. | ||||||||||||||||||||
| 溶解性： | DMSO : ≥ 41 mg/mL (98.35 mM) | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號(hào)
危險(xiǎn)品化學(xué)品經(jīng)營(yíng)許可證（不帶存儲(chǔ)）
營(yíng)業(yè)執(zhí)照(三證合一)
掃一掃關(guān)注上海源葉微信公眾號(hào)
北京